Drug Type Small molecule drug |
Synonyms CAD-9271, MIJ 821 |
Target |
Mechanism GluN2B antagonists(Glutamate [NMDA] receptor subunit epsilon 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H23FN2O3 |
InChIKeyNEFQLCKWVRZEJA-ZDXGLAPJSA-N |
CAS Registry1892581-29-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Suicidal Ideation | Phase 2 | US | 20 Jul 2021 | |
Suicidal Ideation | Phase 2 | JP | 20 Jul 2021 | |
Suicidal Ideation | Phase 2 | AR | 20 Jul 2021 | |
Suicidal Ideation | Phase 2 | BR | 20 Jul 2021 | |
Suicidal Ideation | Phase 2 | CA | 20 Jul 2021 | |
Suicidal Ideation | Phase 2 | DE | 20 Jul 2021 | |
Suicidal Ideation | Phase 2 | MY | 20 Jul 2021 | |
Suicidal Ideation | Phase 2 | MX | 20 Jul 2021 | |
Suicidal Ideation | Phase 2 | NL | 20 Jul 2021 | |
Suicidal Ideation | Phase 2 | PL | 20 Jul 2021 |